We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Regeneron Gets Six Months’ Pediatric Exclusivity for Eylea
Regeneron Gets Six Months’ Pediatric Exclusivity for Eylea
The FDA has granted Regeneron an additional six months of pediatric exclusivity for its intraocular injection Eylea (aflibercept) as a treatment for preterm infants with retinopathy of prematurity (ROP).